Correction: KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC

Correction: KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC

Saved in:

Bibliographic Details
Main Authors:	Jinghan Li, Daiwang Shi, Siyi Li, Xiang Shi, Yu Liu, Yi Zhang, Gebang Wang, Chenlei Zhang, Tian Xia, Hai-long Piao, Hong-Xu Liu
Format:	Article
Language:	English
Published:	Nature Publishing Group 2025-01-01
Series:	Cell Death and Disease
Online Access:	https://doi.org/10.1038/s41419-024-07292-3
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
by: Jinghan Li, et al.
Published: (2024-02-01)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
by: Chiao-En Wu, et al.
Published: (2020-01-01)

Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
by: Chenyue Qian, et al.
Published: (2018-01-01)

KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
by: Linyan Tian, et al.
Published: (2025-01-01)

Quercetin Attenuates Oxidative Stress and Apoptosis in Brain Tissue of APP/PS1 Double Transgenic AD Mice by Regulating Keap1/Nrf2/HO-1 Pathway to Improve Cognitive Impairment
by: Meijia Cheng, et al.
Published: (2024-01-01)

PLUNC downregulates the expression of PD-L1 by inhibiting the interaction of DDX17/β-catenin in nasopharyngeal carcinoma
by: Ranran Feng, et al.
Published: (2025-01-01)

Resveratrol amplifies the anti-tumor effect of α-PD-1 by altering the intestinal microbiome and PGD2 content
by: Baohua Luo, et al.
Published: (2025-12-01)

Targeting Nrf2/KEAP1 signaling pathway using bioactive compounds to combat mastitis
by: Muhammad Zahoor Khan, et al.
Published: (2025-02-01)

miR-432-5p Inhibits the Ferroptosis in Cardiomyocytes Induced by Hypoxia/Reoxygenation via Activating Nrf2/SLC7A11 Axis by Degrading Keap1
by: Wei Geng, et al.
Published: (2023-01-01)

Hyaluronic acid-curcumin nanoparticles for preventing the progression of experimental autoimmune uveitis through the Keap1/Nrf2/HO-1 signaling pathway
by: Weiwei Tang, et al.
Published: (2025-02-01)

Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer
by: Yuanyuan Wang, et al.
Published: (2025-02-01)

ENTPD8 overexpression enhances anti-PD-L1 therapy in hepatocellular carcinoma via miR-214-5p inhibition
by: Si-qi Zhao, et al.
Published: (2025-02-01)

ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling
by: Aziguli Tulamaiti, et al.
Published: (2025-02-01)

Mechanism of SET8 Activates the Nrf2-KEAP1-ARE Signaling Pathway to Promote the Recovery of Motor Function after Spinal Cord Injury
by: Xin Li, et al.
Published: (2023-01-01)

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
by: Solange Peters, et al.
Published: (2023-10-01)

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
by: Meijuan Zhai, et al.
Published: (2025-01-01)

Mesenchymal stem cells enchanced by salidroside to inhibit ferroptosis and improve premature ovarian insufficiency via Keap1/Nrf2/GPX4 signaling
by: Lixuan Chen, et al.
Published: (2025-12-01)

KLF5 promotes esophageal squamous cell carcinoma radioresistance by targeting the Keap1-Nrf2 pathway
by: Yang Wang, et al.
Published: (2025-02-01)

Evaluating the influence of anti-PD-1 immunotherapy combined with IMRT on thyroid dysfunction in nasopharyngeal carcinoma
by: Liqianqi Chen, et al.
Published: (2025-01-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors
by: Anna Hernández‐Prat, et al.
Published: (2025-01-01)

Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies
by: Iza Andrade de A. Souza, et al.
Published: (2024-11-01)

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
by: Huanhuan Yin, et al.
Published: (2020-01-01)

PD-L1 knockout or ZG16 overexpression inhibits PDAC progression and modulates TAM polarization
by: Hui Meng, et al.
Published: (2025-01-01)

Correction: Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
Published: (2023-01-01)

Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
by: Sandip P. Patel, et al.
Published: (2025-01-01)

Protective Effect of Uric Acid on ox-LDL-Induced HUVECs Injury via Keap1-Nrf2-ARE Pathway
by: Yajuan Lin, et al.
Published: (2021-01-01)

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)

Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites
by: Yun Teng, et al.
Published: (2025-02-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

WNT11 Promotes immune evasion and resistance to Anti-PD-1 therapy in liver metastasis
by: Weiliang Jiang, et al.
Published: (2025-02-01)

Bibliometric analysis of the research landscape of PD-1/PD-L1 inhibitors in the treatment of bowel cancer
by: Qingwei Luo, et al.
Published: (2025-02-01)

The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus
by: Joshua A. David, et al.
Published: (2017-01-01)

Procyanidin A1 and its digestive products alleviate acrylamide-induced IPEC-J2 cell damage through regulating Keap1/Nrf2 pathway
by: Fangfang Yan, et al.
Published: (2024-05-01)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
by: Yu Chen, et al.
Published: (2023-01-01)

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model
by: Ismail M Meraz, et al.
Published: (2025-02-01)

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01)

The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment
by: Ze-Tao Zhan, et al.
Published: (2022-01-01)

Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care
by: Drew M Pardoll, et al.
Published: (2025-01-01)

The discovery and characterization of K‐563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp
by: Ran Hori, et al.
Published: (2019-03-01)